“With his track record of turning science into life-changing medicines, he brings rigor and vision to help shape our strategy for the next generation of therapies. This week’s SAB focused on how to best prioritize the broad potential of mRNA as a therapeutic modality. There was a wealth of creative thinking, including considerations of when and how to use iMSC as well as the Extroducer. Achieving targeted and effective therapeutic delivery remains a major challenge across many disease areas. The SAB reached a clear consensus to prioritize exploring renal and fibrotic conditions as promising focus areas,” says Anna Martling, Chairperson of the company’s Scientific Advisory Board.

Jan Lundberg

Professor Jan Lundberg is a Swedish pharmacologist and life sciences executive with a career bridging academia and global pharma. Formerly Global Head of R&D at Eli Lilly and AstraZeneca, he has led the research and development of over 250 drug candidates, resulting in several approved products including Mounjaro (type 2 diabetes), Zepbound (obesity), Taltz (psoriasis), Kisunla (Alzheimer’s disease), and Verzenio (breast cancer). He is also a former professor of pharmacology at Karolinska Institutet with more than 500 scientific papers published. Jan Lundberg has received several major awards, including the Fernström and Jahres prizes, and is an honorary doctor at Uppsala University.

Related article

Jan Lundberg: The long view of R&D at Eli Lilly

Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]